Fluctuating antibody response in a cohort of hepatitis C patients
- PMID: 24019724
- PMCID: PMC3174718
Fluctuating antibody response in a cohort of hepatitis C patients
Abstract
Objective: This project was designed to longitudinally study persons who had antibodies to hepatitis C virus (HCV) to characterise the serologic course of infection.
Methods: The subjects were 149 multitransfused patients (141 with thalassaemia major, 3 with thalassaemia intermedia, and 5 with sickle cell anaemia) who had been regularly followed up for 3 to 7 years. Sequential serum samples obtained semi-annually between January 1994 and January 2001 were tested, prospectively, by second or third generation HCV enzyme-linked immunosorbent assay (ELISA), followed by confirmatory recombinant immunoblot assay (RIBA-2 or RIBA-3).
Results: Of the 149 patients, 90 did not seroconvert to HCV, whereas 59 had detectable antibodies. On the basis of RIBA results in these 59 patients, 24 (41%) had persistent high antibody levels to structural and non structural HCV antigens, 11 (19%) had persistent low antibody levels, 17 (29%) showed fluctuating antibody levels, and in 5 patients (8%) there was a total or a partial disappearance of specific antibodies (seroreversion), mainly anti-core antibodies. Two patients (3%) had antibody responses that did not fit into any of these four categories. In patients with fluctuating antibody levels, there were periods ranging from 6 months to 2 years when anti-HCV antibodies could not be detected.
Conclusion: This study shows that the antibody response to HCV in patients who receive frequent blood transfusions is very variable. Individuals who exhibit intermittent seropositivity are a challenge to diagnosis.
Keywords: antibody response; hepatitis C virus; thalassaemia.
Figures





Similar articles
-
Prevalence and serological manifestation of hepatitis C virus infection in patients with hepatitis non-A, non-B: a follow-up study.Presse Med. 1994 Apr 30-May 7;23(17):793-6. Presse Med. 1994. PMID: 8078836
-
Characterization of differential antibody production against hepatitis C virus in different HCV infection status.Virol J. 2016 Jun 30;13:116. doi: 10.1186/s12985-016-0572-9. Virol J. 2016. PMID: 27357382 Free PMC article.
-
Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors.J Med Virol. 1993 Jan;39(1):57-61. doi: 10.1002/jmv.1890390111. J Med Virol. 1993. PMID: 7678638
-
Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.Hepatology. 1999 Apr;29(4):1288-98. doi: 10.1002/hep.510290442. Hepatology. 1999. PMID: 10094977
-
[Anti-HCV serology for screening, diagnosis and surveillance of hepatitis C: role of the immunoblot].Ann Biol Clin (Paris). 1998 Jul-Aug;56(4):417-26. Ann Biol Clin (Paris). 1998. PMID: 9754277 Review. French.
Cited by
-
Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.Hepatology. 2021 Sep;74(3):1148-1163. doi: 10.1002/hep.31802. Epub 2021 Jun 11. Hepatology. 2021. PMID: 33713356 Free PMC article.
References
-
- Choo Q-L, Kuo G, Weiner A, Overby L, Bradley D, Houghton M. Isolation of a cDNA clone derived from a blood-borne viral hepatitis genome. Science. 1989;244:359–362. - PubMed
-
- van der Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet. 1994;344:1475–1479. - PubMed
-
- Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis. N Eng J Med. 1995;332:1463–1466. - PubMed
-
- Alter HJ, Seef LB. Recovery, persistence, and sequelae in hepatitis C infection: a perspective on long-term outcome. Sem Liver Disease. 2000;20:17–35. - PubMed
-
- Herrine SK, Weinberg DS. Epidemiology of hepatitis C viral infection. Infect Med. 1999;16:111–117.
LinkOut - more resources
Full Text Sources